In this translational study, we show that oncolytic adenovirus treatment can reduce TIM-3 levels on CD8+ tumor-infiltrating lymphocyte (TIL) in both animals and in patient tumors, with correlation to improved overall survival. This evidence concerns the gene CD8A and neoplasm.